Shares of Cogent Biosciences, Inc. (NASDAQ:COGT – Get Free Report) have received an average rating of “Moderate Buy” from the ...

Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its target price reduced by Needham & Company LLC from $202.00 to $183.00 in a report published on Thursday,Benzinga reports. Needham & Company LLC ...

The actress, 31, has found worldwide fame thanks to her role in The White Lotus, and in a new interview, revealed she went ...

Snook gives a master class, playing 26 characters in an adaptation of the Oscar Wilde novel that’s hideously apt for our age ...

It sidesteps constitutional guarantees to sanction state intervention into the religious affairs of a community, barely ...

On Tuesday, based on data from those with estrogen receptor 1 (ESR1m) mutations, the duo said that ... Wedbush's Robert Driscoll downgraded ARVN to Neutral from Outperform, while expecting the ...

Q4 2024 Earnings Call Transcript April 1, 2025 Operator: Good afternoon ladies and gentlemen and thank you for standing by.

Regenxbio is ranked Strong Buy due to low EV, strong partnerships, royalty income, bullish trends, and buyout potential. Click to read why RGNX is a Strong Buy.

China’s Ministry of Commerce has pledged a “fair and objective” decision in an ongoing anti-dumping investigation that could ...